EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study

Hiromitsu Imai, Ichiro Oikawa, Tetsuya Koyama, Shunji Matsuki

British Journal of Clinical Pharmacology · 2024

DOI: 10.1111/bcp.16024 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2024. Verfasst von Hiromitsu Imai und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ethics, Oita University Faculty of Medicine, Oita, Japan. Hauptthemen laut MEDLINE: Rifampin, Cross-Over Studies, Drug Interactions, Area Under Curve. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: EA Pharma Co., Ltd., Kissei Pharmaceutical Co., Ltd., Kissei.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To evaluate the effect of the combination of carotegrast methyl with rifampicin, a potent inhibitor of organic anion transporter polypeptide, on the pharmacokinetics (PKs), safety and tolerability of carotegrast methyl.

Methods

In this 2 × 2 crossover study in 20 healthy Japanese adults, 10 subjects received carotegrast methyl 960 mg and rifampicin 600 mg on day 1 and received carotegrast methyl 960 mg on day 8. The subjects in the other sequence received the same treatments but in the opposite order. The 90% confidence interval (CI) of the geometric mean ratio of the C max and AUC 0‐ t for carotegrast, the main active metabolite of carotegrast methyl, with/without rifampicin was calculated. If the 90% CI fell within the range of 0.80‐1.25, this indicated the absence of any drug‐drug interaction. Adverse events (AEs) were monitored.

Results

The geometric mean ratios (90% CI) of the C max and AUC 0‐ t for carotegrast with/without rifampicin were 4.78 (3.64‐6.29) and 5.59 (4.60‐6.79), respectively, indicating that carotegrast has a PK interaction with rifampicin. The combination with rifampicin increased the exposure of carotegrast and also that of its metabolites. The incidence of any AEs with/without rifampicin was five (25.0%) and one (5.0%), respectively.

Conclusions

Coadministration of carotegrast methyl with rifampicin significantly increased the exposure of carotegrast compared with carotegrast methyl administration alone. In this single dose study, the incidence of AEs of carotegrast methyl with rifampicin increased compared with carotegrast methyl alone, but the incidence of adverse drug reactions did not increase with combination administration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RifampinCross-Over StudiesDrug InteractionsArea Under CurveHealthy VolunteersHumansMaleAdultFemaleYoung AdultOrganic Anion Transporters

Stichwörter der Autor:innen

AJM300OATP1B1OATP1B3carotegrast methyldrug‐drug interactionpharmacokineticsrifampicin

Substanzen

RifampinOrganic Anion Transporters

Autor:innen und Institutionen

  • Department of Medical Ethics, Oita University Faculty of Medicine, Oita, Japan.
  • Clinical Development Department, EA Pharma Co., Ltd., Tokyo, Japan.
  • Department of Clinical Research Center, Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan.

Förderung

  • EA Pharma Co., Ltd.
  • Kissei Pharmaceutical Co., Ltd.
  • Kissei

Zitieren

APA

Imai, H., Oikawa, I., Koyama, T., & Matsuki, S. (2024). Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16024

Vancouver

Imai H, Oikawa I, Koyama T, Matsuki S. Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study. British Journal of Clinical Pharmacology. 2024. doi:10.1111/bcp.16024

BibTeX
@article{Imai2024,
  author = {Imai, Hiromitsu and Oikawa, Ichiro and Koyama, Tetsuya and Matsuki, Shunji},
  title = {Effects of rifampicin on the pharmacokinetics and safety of carotegrast methyl in healthy subjects: A randomized 2 × 2 crossover study},
  journal = {British Journal of Clinical Pharmacology},
  year = {2024},
  doi = {10.1111/bcp.16024}
}
Kostenlos starten →